Overview

Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to demonstrate the efficacy and safety of quetiapine fumarate (SEROQUEL) in the treatment of adolescent patients with schizophrenia and bipolar I disorder.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Treatments:
Quetiapine Fumarate
Criteria
Inclusion Criteria:

- Patient is able to provide written assent and the parents or legal guardian of the
patient are/is able to provide written informed consent before beginning any study
related procedures

- Patient previously enrolled in either double-blind Study D1441C00149 or D1441C00112

- Patient has documented clinical diagnosis of schizophrenia or bipolar I disorder

- Patient's parent or legal guardian will be able to accompany the patient to each
scheduled study visit

Exclusion Criteria:

- Patients (female) must not be pregnant or lactating

- Patients with a known intolerance or lack of response to previous treatment with
quetiapine

- Patients who have previously participated in this study